ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · CHMP positive opinion

Sintilimab (Zybrivo)

Treatment of non-squamous non-small cell lung cancer in adults.

CHMP opinion 12 Nov 2026 · Fortvita Biologics (Ireland) Limited

Research

Oncology · Sci Bull (Beijing) · 2023-12-26

Phase 2 trial, 71 untreated advanced NSCLC patients: PD-L1-guided sintilimab (alone if PD-L1 ≥50%, plus chemotherapy if <50%) met its primary endpoint (confirmed ORR 51.4%), similar to pembrolizumab; rash was commoner with sintilimab alone.

RCTn = 71
Maggie Liu et al. PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.